# How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians

**Authors:** Ritika Prasad, Radhika Arya, Lina Meng, Marisa Holubar, William Alegria, Alex N. Zimmet

PMC · DOI: 10.1017/ash.2025.10189 · Antimicrobial Stewardship & Healthcare Epidemiology : ASHE · 2025-10-13

## TL;DR

This paper explains how physicians can use Medication Use Evaluations to support antimicrobial stewardship goals and improve healthcare practices.

## Contribution

The paper provides guidance for physicians on engaging in MUEs, which is a gap in their training.

## Key findings

- MUEs can help ASPs address antimicrobial concerns like safety and cost.
- MUEs promote interdisciplinary collaboration and trainee involvement in stewardship projects.
- Stewardship physicians can contribute effectively to MUEs without prior experience.

## Abstract

Medication Use Evaluations (MUEs) are structured quality improvement tools used to optimize medication use within healthcare systems. MUEs can explore safety concerns, high costs, or inappropriate use associated with any medication, among other factors. This can offer a valuable opportunity for Antimicrobial Stewardship Programs (ASPs) to promote stewardship goals, which often overlap with these concerns for specific antimicrobials. MUEs can also provide an avenue to promote interdisciplinary collaboration with targeted groups relevant to the ASP’s goals as well as an opportunity to give trainees ownership of system-facing stewardship projects. Stewardship pharmacists may often have experience with leading this process as part of their training, but MUEs represent a gap in training for physicians. Here we provide guidance on how stewardship physicians can engage in the MUE process, from identifying relevant topics to interpreting findings and supporting implementation efforts, allowing them to contribute effectively even without prior MUE experience.

## Full-text entities

- **Genes:** ASPM (assembly factor for spindle microtubules) [NCBI Gene 259266] {aka ASP, Calmbp1, MCPH5}
- **Diseases:** infectious diseases (MESH:D003141), CMV (MESH:D003586), pneumonia (MESH:D011014), ID (MESH:C537985)
- **Chemicals:** beta-lactams (MESH:D047090), levofloxacin (MESH:D064704), fidaxomicin (MESH:D000077732), piperacillin/tazobactam (MESH:D000077725)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12538338/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12538338/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12538338/full.md

---
Source: https://tomesphere.com/paper/PMC12538338